Clinical Observation of Immunotherapy Efficacy and Adverse Effects in Chinese Patients with Lung Squamous Cell Carcinoma
This study aimed to investigate the efficacy and toxicity of immunotherapy in patients with LUSC in Chinese population of real world. Methods A total of 185 LUSC patients underwent pathological diagnosis were involved from January 2018 to January 2022. Patients were divided into elderly group (age ≥70 years) and younger group (age0.05). Both combined group and immunology alone demonstrated prolonged mPFS in first-line compared with chemotherapy in elderly group. And combined group demonstrated significantly prolonged mPFS compared with chemotherapy in younger group (P
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | China Health | Immunotherapy | Lung Cancer | Skin Cancer | Squamous Cell Carcinoma | Study | Toxicology